Actively Recruiting

Phase Not Applicable
Age: 19Years +
All Genders
NCT07421869

SNUH Immune Checkpoint Inhibitor-induced Hypothyroidism Recovery Trial

Led by Seoul National University Bundang Hospital · Updated on 2026-02-19

107

Participants Needed

1

Research Sites

246 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The goal of this study is to find out whether hypothyroidism caused by immune checkpoint inhibitors (ICIs) can recover after stopping the ICIs. The study also aims to identify factors that can help predict which patients will be able to stop taking thyroid hormone replacement. The main questions the study will answer are: * What percentage of patients recover normal thyroid function and can stop levothyroxine after stopping ICIs? * What clinical or laboratory factors can predict successful withdrawal of levothyroxine? Participants will: * Be adult cancer patients who developed hypothyroidism during ICI treatment and are currently taking levothyroxine * Have already stopped ICI therapy * Gradually reduce their levothyroxine dose every 3 months if their thyroid function remains normal * Stop levothyroxine if thyroid function remains normal at low doses (≤0.025 mg) * Be monitored with thyroid function tests and clinical symptoms at each visit

CONDITIONS

Official Title

SNUH Immune Checkpoint Inhibitor-induced Hypothyroidism Recovery Trial

Who Can Participate

Age: 19Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Adults aged 19 years or older.
  • Patients with a history of treatment with immune checkpoint inhibitors (ICIs).
  • Developed hypothyroidism during ICI treatment and started levothyroxine after starting ICI therapy.
  • Discontinued ICI therapy before joining the study.
Not Eligible

You will not qualify if you...

  • Use of levothyroxine or antithyroid medications within 3 months before starting ICI therapy.
  • History of thyroid surgery, radioactive iodine therapy, or neck radiation therapy.
  • Current levothyroxine dose of 0.1 mg or higher when enrolling.

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Department of Internal Medicine, Seoul National University Bundang Hospital

Seongnam-si, South Korea

Actively Recruiting

Loading map...

Research Team

M

Min Joo Kim, Professor

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here